Table 3 |
||||||||||||
|
Changes in WOMAC Scores at baseline and at the end of the trial Between and Within Groups (ITT-LOCF) |
||||||||||||
| Variable |
Pain Baseline |
Pain End |
Pain baseline – pain end |
Stiffness Baseline |
Stiffness End |
Stiffness baseline – stiffness end |
Activity Baseline |
Activity End |
Activity baseline – activity end |
Composite Baseline |
Composite End |
Composite baseline – composite end |
|
|
||||||||||||
| PBO |
50.0 |
52.9 |
-2.9 |
40.4 |
46.3 |
-5.9 |
49.4 |
56.4 |
-7.0 |
48.8 |
54.8 |
-6.1 |
| SD |
22.9 |
21.4 |
19.9 |
17.4 |
25.3 |
18.3 |
23.1 |
24 |
18.4 |
21.8 |
22.7 |
17.6 |
| Sig.* |
NS |
NS |
NS |
NS |
||||||||
| A |
56.8 |
74.3 |
-17.5 |
44.4 |
65 |
-20.6 |
58.8 |
72.4 |
-13.5 |
57.3 |
72.2 |
-14.9 |
| SD |
15.8 |
17.6 |
22.7 |
17 |
17.5 |
26.1 |
16.2 |
16.8 |
21.3 |
15.3 |
16.6 |
21.4 |
| Sig.* |
.0.003 |
0.002 |
0.01 |
0.006 |
||||||||
| GS |
60.6 |
72.9 |
-12.6 |
51.3 |
61.8 |
-10.5 |
60.1 |
70.7 |
-10.6 |
59.4 |
70.2 |
-10.9 |
| SD |
14.8 |
17.6 |
16.3 |
13.8 |
19.8 |
24.0 |
13.9 |
18.4 |
15.4 |
13.2 |
17.6 |
15.6 |
| Sig.* |
0.003 |
NS |
0.008 |
0.007 |
||||||||
| G+A |
67.2 |
69.1 |
-1.9 |
57.8 |
64.1 |
-6.3 |
63 |
68.6 |
-5.6 |
63.4 |
68.3 |
-4.9 |
| SD |
13.3 |
16.9 |
14.0 |
15.7 |
17.6 |
17.7 |
8.7 |
13.1 |
11.0 |
8.1 |
12.9 |
101 |
| Sig.* |
NS |
NS |
NS |
NS |
||||||||
| p(ANCOVA) |
0.039# |
0.009 |
0.013# |
NS |
NS# |
NS |
NS# |
NS |
||||
|
|
||||||||||||
|
*Sig. = significance by within group paired t-test; 2-tailed; ANCOVA comparison between groups with baseline measure as covariate. # = ANCOVA comparison between groups showing any differences at baseline for these parameters. |
||||||||||||
|
Frestedt et al. Nutrition Journal 2008 7:9 doi:10.1186/1475-2891-7-9 |
||||||||||||
